[1] DUMA N,SANTANA-DAVILA R,MOLINA JR. Non-small cell lung cancer:epidemiology,screening,diagnosis,and treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.
[2] ALEXANDER M,KIM S Y,CHENG H. Update 2020:management of non-small cell lung cancer[J].Lung,2020,198(6):897-907.
[3] JONNA S,SUBRAMANIAM D S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC):an update[J].Discov Med,2019,27(148):167-170.
[4] 王岩,闵波,朱逸,等. miR-486在非小细胞肺癌患者外周血中表达水平及对预后的预测价值分析[J].哈尔滨医科大学学报,2021,55(3):282-285.
[5] 吴一龙,廖美琳. 局部晚期非小细胞肺癌诊断治疗之共识[J].中华肿瘤杂志,2002,24(6):576-578.
[6] 陈俊,钱璞,赵婷婷,等. 非小细胞肺癌组织中miR-497与患者临床病理特征及预后的关系[J].标记免疫分析与临床,2020,27(7):1203-1207.
[7] BRODERICK S R. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer[J].Thorac Surg Clin,2020,30(2):215-220.
[8] 钟有清,周向东,李琪,等. miR-506通过调控MCL-1抑制耐阿立替尼非小细胞肺癌A549细胞上皮间质转化的作用机制[J].现代肿瘤医学,2021,29(2):190-195.
[9] 应朝辉,隗玉川,程万宏. microRNA-130b的表达对靶向治疗肺腺癌患者预后的影响[J].中国肿瘤外科杂志,2020,12(2):153-157.
[10] SANKAR K,GADGEEL S M,QIN A. Molecular therapeutic targets in non-small cell lung cancer[J].Expert Rev Anticancer Ther,2020,20(8):647-661.
[11] 金澄宇,杨勇伟. 非小细胞肺癌患者胸腔镜与开胸手术前后血清肿瘤标志物及血浆miR相关指标和创伤应激指标变化比较[J].生物医学工程与临床,2018,22(3):327-332.
[12] BROWN S,BANFILL K,AZNAR M C,et al. The evolving role of radiotherapy in non-small cell lung cancer[J].Br J Radiol,2019,92(14):524-526.
2023, Vol. 40 
